Late treatment study
et al., JAMA, May 11, 2020, doi:10.1001/jama.2020.8630 (Peer Reviewed)
Association of Treatment With Hydroxych loroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Restrospective observational late stage study showing no significant differences but calling for clinical trials.
Zervos et al.  point out serious limitations that they say should be corrected on the record: patients receiving HC
Q with or without AZ were overall sicker on presentation and had multiple other risk factors including much higher risk based on ethnicity; patients receiving HC
Q were more likely to be obese, diabetic, have chronic lung disease, and cardiovascular conditions; yet these sicker patients had approximately the same mortality rates compared to patients with a milder course of the disease and less risk factors. However, the authors conclude that "there are no significant benefits." It is noteworthy that HC
Q was associated with a significant survival benefit in a larger cohort of patients from New York City as reported by Mikami et al .
Please send us corrections, updates, or comments.